Norwich Pharmaceuticals v. Kennedy — D.C. Circuit: Amended ANDA Cannot Escape Hatch-Waxman Patent Bar
The D.C. Circuit held that a generic drugmaker cannot escape a Hatch-Waxman patent judgment by amending its drug application — the bar on FDA approval runs to the application number itself, not to any particular labeled indication.